Author
Listed:
- Alicia Ramírez-Orellana
- Silvia Giralt-Escobar
- Cristina Blanco-González-Tejero
Abstract
PurposeThis paper explores effective management strategies to optimise corporate value in the pharmaceutical industry. It uses key variables such as research and development (R&D), board gender diversity, and environmental, social and governance (ESG) factors.Design/methodology/approachGiven the dynamic and multifaceted nature of corporate innovation and its impact on performance, 53 pharmaceutical companies were examined using partial least squares structural equation modelling (PLS-SEM). This methodology enabled exploration of causal and predictive relationships in corporate value and management.FindingsGreater investment in R&D drives innovation and future growth. Despite the short-term financial impact, R&D investment reflects a strategic emphasis on long-term growth and sustainability in the pharmaceutical industry. Management effectiveness mediates the effects of gender diversity on increasing corporate value. The ESG score is the least relevant variable for assessing the value of pharmaceutical companies. It contributes to improving management practices but is not fully considered in the overall corporate value of a company taking into account the selected database.Practical implicationsPharmaceutical companies can use these findings to adjust and optimise their investment in R&D. They can thus direct their strategies towards more ethical and sustainable practices, thereby enhancing effectiveness and competitiveness. The combination of these elements provides an opportunity to develop integrated management strategies.Originality/valueThis research explores innovative strategies to enhance corporate value, emphasising the pivotal role of R&D and ESG factors. It reveals the intricacies of the pharmaceutical landscape and provides solutions for organisational strategy.
Suggested Citation
Alicia Ramírez-Orellana & Silvia Giralt-Escobar & Cristina Blanco-González-Tejero, 2024.
"Exploring management strategies to optimise corporate value,"
European Journal of Innovation Management, Emerald Group Publishing Limited, vol. 28(8), pages 4177-4201, December.
Handle:
RePEc:eme:ejimpp:ejim-04-2024-0396
DOI: 10.1108/EJIM-04-2024-0396
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eme:ejimpp:ejim-04-2024-0396. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Emerald Support (email available below). General contact details of provider: .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.